← All indications
Anemia, Aplastic
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
Subtype terms (1)
More specific conditions that are subtypes of Anemia, Aplastic in the MeSH hierarchy.
- Anemia, Hypoplastic, Congenital
1 drug experimental
Drugs by status
Approved for this indication (4)
Phase 4 trials (15)
Phase 3 trials (14)
Phase 2 trials (53)
- decitabine
- norgestrel
- anti cd45 monoclonal antibody
- acetylcysteine
- bkt-140
- bpx-501
- cd3,cd19 depleted hematopoietic stem cells
- clofarabine
- daclizumab
- danazol
- parathyroid hormone
- tacrolimus
- ethinyl estradiol
- naltrexone
- hemopoietic stem cell
- bone marrow derived mesenchymal stem cells
- haploidentical mononuclear cells
- Filgrastim
- levamisole
- ibrutinib
- peripheral blood lymphocytes
- carmustine
- allogeneic hematopoietic stem cells
- alirocumab
- ruxolitinib
- sirolimus
- mycophenolate
- abatacept
- t cell depleted hematopoietic stem cells
- allogeneic lymphocytes
- +23 more
Phase 1 trials (11)
Organizations
Organization Involved with Phase 4 Indications (24)
- Novartis
- Huazhong University of Science and Technology
- University of Arizona
- University of London
- Guangzhou Medical University
- Harbin Medical University
- Jinhua Central Hospital
- Linyi People's Hospital
- Nanjing Medical University
- Qingdao University
- Shengjing Hospital
- Assiut University
- Zhejiang Chinese Medical University
- Jiao Tong University
- Tai'an Central Hospital
- Jining NO.1 People 's Hospital
- Weifang Medical University
- Shandong University of Traditional Chinese Medicine
- Shandong Cord Blood Bank
- Qingdao Center Medical Group
- Yishui Central Hospital of LINYI
- Jiangxi Provincial People's Hospital
- People's Liberation Army of China
- Chinese Academy of Medical Sciences
Organization Involved with Phase 3 Indications (21)
- Pfizer
- Chugai
- Hengrui Therapeutics, Inc.
- Kyowa Hakko Kirin
- Sponsor GmbH
- National Institutes of Health (NIH)
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- National Heart, Lung, and Blood Institute (NHLBI)
- European Group for Blood and Marrow Transplantation
- Nagoya University
- University of Alberta
- University of Bern
- University of Calgary
- University of Naples Frederico II
- University of Ulm
- University of Ulsan
- University of Minnesota
- Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and Immunology
- Paris Diderot University
- State University of New York, Buffalo
- Government of Japan
Organization Involved with Phase 2 Indications (72)
- Regeneron
- Amgen
- Genzyme
- Bayer
- Bellicum Pharmaceuticals
- BioLineRx, Ltd.
- Cellphire, Inc.
- Texas Oncology Cancer Center
- The EMMES Corporation
- German Research Foundation
- Burnasyan Federal Medical Biophysical Center
- Center for International Blood and Marrow Transplant Research
- National Cancer Institute (NCI)
- National Center for Research Resources (NCRR)
- National Marrow Donor Program
- Rockefeller University
- Baylor University
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Cornell University
- Harvard University
- Duke University
- University of Washington
- Indiana University
- Julius-Maximilians University
- King Faisal University
- Johns Hopkins University
- Medical College of Wisconsin
- New York Medical College
- Northside Hospital, Inc.
- Northwell Health
- +42 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (6)